Immunovant Provides Update on Graves’ Disease Development Program
September 09, 2024 03:55 ET
|
Immunovant Inc.
High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on ATDs...
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
September 05, 2024 06:30 ET
|
Immunovant Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
August 06, 2024 16:05 ET
|
Immunovant Inc.
Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31,...
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
May 29, 2024 16:01 ET
|
Immunovant Inc.
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and...
Immunovant Awarded U.S. Patent for IMVT-1402
March 12, 2024 07:30 ET
|
Immunovant Inc.
Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant,...
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
February 12, 2024 07:00 ET
|
Immunovant Inc.
Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two...
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Immunovant Inc.
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023 16:30 ET
|
Immunovant Inc.
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28, 2023 07:00 ET
|
Immunovant Inc.
Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG...
Immunovant to Present at Upcoming Investor Conferences
November 13, 2023 08:00 ET
|
Immunovant Inc.
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...